Page last updated: 2024-08-21

pyrazines and Waldenstrom Macroglobulinemia

pyrazines has been researched along with Waldenstrom Macroglobulinemia in 52 studies

Research

Studies (52)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (32.69)	29.6817
2010's	32 (61.54)	24.3611
2020's	3 (5.77)	2.80

Authors

Authors	Studies
Castillo, JJ; Treon, SP	1
Aurran-Schleinitz, T; Chen, DY; Cheson, BD; D'Sa, S; Forconi, F; Frigault, MM; Furman, RR; Greenwald, D; Hamdy, A; Iyengar, S; Izumi, R; Kastritis, E; Kersten, MJ; Kothari, J; Lee, SK; McCarthy, H; Minnema, MC; Mittag, D; Owen, RG; Patel, P; Rule, S; Thomas, SK; Tournilhac, O; Walter, H; Wei, H; Zinzani, PL	1
Lim, KJC; Tam, CS	1
Castillo, JJ; Sarosiek, S; Treon, SP	1
Andorsky, DJ; Assouline, S; Forero-Torres, A; Jones, V; Klein, LM; Kolibaba, KS; Patel-Donnelly, D; Sharman, JP; Shi, W; Smith, M; Yasenchak, CA; Ye, W	1
Azzarà, A; Carulli, G; Ciabatti, E; Ciancia, EM; Ferreri, MI; Grassi, S; Marini, A; Ottaviano, V; Petrini, M; Rocco, M	1
Bakhous, A; Waheed, S; Zhu, H	1
Dimopoulos, MA; García-Sanz, R; Gavriatopoulou, M; Gika, D; Kartasis, Z; Kastritis, E; Kyrtsonis, MC; Leleu, X; Merlini, G; Michalis, E; Morel, P; Palladini, G; Sonneveld, P; Tedeschi, A	1
Akhtar, S; Ansell, SM; Carr, J; Chanan-Khan, A; Chitta, K; Dispenzieri, A; Foran, J; Kumar, S; Mikhael, JR; Miller, KC; Paulus, A; Personett, D; Reeder, CB; Rivera, CE; Roy, V; Thompson, KJ	1
Matsue, K; Morita, T; Tanimoto, T; Ugai, T	1
Adam, Z; Krejčí, M; Pour, L; Ševčíková, E	1
Choquet, S; Leblond, V; Nguyen, S; Souchet-Cömpain, L	1
Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP	1
Pallavi, R	1
Castillo, JJ; Ghobrial, IM; Treon, SP	1
Castillo, JJ; Ghobrial, IM; Leblebjian, H; Noonan, K; Paba-Prada, C; Treon, SP	1
Oza, A; Rajkumar, SV	1
Treon, SP	1
Dimopoulos, MA; Kastritis, E; Rajkumar, SV	1
Dimopoulos, MA; Fermand, JP; Garcia-Sanz, R; Gertz, MA; Ghobrial, IM; Kastritis, E; Kimby, EK; Kyle, RA; Leblond, V; Merlini, G; Morel, P; Morra, E; Ocio, EM; Owen, R; Seymour, J; Treon, SP	1
Anderson, KC; Azab, AK; Azab, F; Burwick, N; Chen, C; Ghobrial, IM; Jia, X; Leleu, X; Melhem, MR; Ngo, HT; Novina, CD; Roccaro, AM; Rollins, BJ; Runnels, J; Sacco, A; Varticovski, L	1
Balkaran, S; Gay, J; Ghobrial, I; Leleu, X; Morel, P; Pascal, L; Robu, D; Roccaro, A; Wemeau, M; Willekens, C	1
Chen, C; Eisenhauer, E; Kouroukis, CT; Powers, J; Stadtmauer, E; Stewart, AK; Voralia, M; Walsh, W; White, D; Wright, JJ	1
Azab, AK; Azab, F; Ghobrial, IM; Jia, X; Leleu, X; Melhem, M; Moreau, AS; Ngo, HT; Roccaro, AM; Runnels, J; Sacco, A	1
Anderson, KC; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Richardson, PG; Roccaro, AM	1
Birner, A; Boral, A; Diener, JG; Esseltine, DL; Ghobrial, IM; Ioakimidis, L; Keogh, GP; Matous, J; Mattern, J; Myers, TJ; Nelson, M; Patterson, CJ; Sheehy, P; Soumerai, JD; Treon, SP; Willen, M	1
Anderson, KC; Badros, A; Chuma, S; Ghobrial, IM; Harris, B; Hong, F; Kunsman, J; Leduc, R; Matous, J; Padmanabhan, S; Richardson, PG; Rourke, M; Sam, A; Treon, SP; Warren, D; Weller, E	1
Balkaran, S; Daudignon, A; Fernandez, J; Hautecoeur, A; Hivert, B; Lai, JL; Leleu, X; Lepelley, P; Morel, P; Poulain, S; Rossignol, J; Roumier, C; Soenen, V; Wemeau, M	1
Chen, C; Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Treon, SP	1
Anderson, KC; Badros, A; Chuma, S; Ghobrial, IM; Harris, B; Kunsman, J; Leduc, R; Matous, J; Padmanabhan, S; Poon, T; Richardson, PG; Rourke, M; Sam, A; Treon, SP; Warren, D; Weller, E; Xie, W	1
Agathocleous, A; Hunter, H; Johnson, P; Kerr, JP; Lister, A; Matthews, J; Montoto, S; Neeson, SM; Radford, J; Rohatiner, A; Rule, S; Strauss, S	1
Aujay, M; Azab, AK; Azab, F; Ghobrial, IM; Issa, GC; Liu, Y; Maiso, P; Morgan, B; Ngo, HT; Quang, P; Roccaro, AM; Sacco, A; Zhang, Y	1
Bagshaw, M; Banwait, R; Ghobrial, IM; Leduc, R; Leleu, X; Roper, N; Weller, E; Xie, W	1
Cahu, X; Dauriac, C; Houot, R; Lamy, T; Marchand, T; Tas, P	1
Dreyling, M	1
Ciccarelli, B; Fulciniti, M; Gong, P; Hatjiharissi, E; Hunter, ZR; Ioakimidis, L; Liu, X; Maghsoudi, K; Munshi, NC; O'Connor, OA; Patterson, CJ; Sheehy, P; Sun, JY; Treon, SP; Tseng, H; Xu, L; Yang, G; Zhou, Y; Zhu, B	1
Ciccarelli, B; Fulciniti, M; Gong, P; Hunter, Z; Liu, X; Maghsoudi, K; Munshi, NC; Patterson, CJ; Sun, JY; Treon, SP; Tseng, H; Xu, L; Yang, G; Zhou, Y; Zhu, B	1
Bagshaw, M; Banwait, R; Campigotto, F; Ghobrial, IM; Harris, B; Leduc, R; Leleu, X; O'Regan, K; Ramaiya, N; Weller, E; Yarar, D	1
Ghobrial, IM; Roccaro, AM; Sacco, A	1
Gertz, M	1
Azab, AK; Azab, F; Banwait, R; Flores, L; Ghobrial, IM; Jia, X; Maiso, P; Manier, S; Roccaro, AM; Sacco, A	1
Hanzis, C; Hunter, ZR; Ioakimidis, L; Manning, RJ; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, C; Turnbull, B	1
Anderson, KC; Ansell, SM; Garcia-Sanz, R; Gertz, MA; Ghobrial, IM; Joshua, DE; Kastritis, E; Kimby, E; Kyle, RA; Leblond, V; Leleu, X; Merlini, G; Morel, P; Morice, WG; Morra, E; Munshi, NC; Ocio, EM; Owen, RG; Patterson, CJ; Rawstron, AC; Stone, MJ; Tedeschi, A; Terpos, E; Treon, SP	1
Anderson, KC; Mitsiades, CS; Mitsiades, N; Richardson, PG; Treon, SP	1
Leblond, V	1
Anagnostopoulos, A; Bitsaktsis, A; Castritis, E; Dimopoulos, MA; Kyrtsonis, MC; Pangalis, GA	1
Nguyen, CA; Romaguera, J; Wang, M; Zhang, L; Zhou, Y	1
Chen, CI; Eisenhauer, E; Kouroukis, CT; Powers, J; Stadtmauer, E; Stewart, AK; Voralia, M; Walsh, W; White, D; Wright, JJ	1
Advani, R; Badros, A; Branagan, AR; Cook, D; Hill, J; Hunter, ZR; Joyce, RM; Kaden, BR; Leleu, X; Mannion, B; Matous, J; Sharon, D; Songer, J; Steiss, R; Treon, SP	1
Anderson, KC; Azab, A; Azab, F; Burwick, N; Chauhan, D; Farag, M; Ghobrial, IM; Hideshima, T; Jia, X; Leleu, X; Melhem, M; Moreau, AS; Ngo, HT; Palladino, MA; Roccaro, AM; Runnels, J; Sacco, A; Treon, SP	1
Anderson, KC; Azab, A; Azab, F; Brown, M; Burwick, N; Carrasco, DR; Eeckhoute, J; Farag, M; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Hunter, Z; Jia, X; Leleu, X; Melhem, MR; Moreau, AS; Ngo, HT; Roccaro, AM; Runnels, J; Sacco, A; Treon, SP; Witzig, TE	1
Anderson, KC; Ciccarelli, B; Dammacco, F; Ghobrial, IM; Hatjiharissi, E; Jia, X; Leleu, X; Moreau, AS; Ngo, HT; Patterson, CJ; Roccaro, AM; Russo, D; Sacco, A; Treon, SP; Vacca, A; Xu, L	1

Reviews

20 review(s) available for pyrazines and Waldenstrom Macroglobulinemia

Article	Year
What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia, 2019, Volume: 33, Issue:11 Topics: Adenine; Antibodies, Monoclonal; Antigens, CD20; Benzamides; Bone Marrow; Disease-Free Survival; Hematology; Humans; Immunoglobulin M; Mutation; Piperidines; Proteasome Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Waldenstrom Macroglobulinemia	2019
Zanubrutinib for the treatment of Waldenström Macroglobulinemia. Expert review of hematology, 2020, Volume: 13, Issue:12 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Atrial Fibrillation; Benzamides; Central Nervous System Diseases; Clinical Trials as Topic; Febrile Neutropenia; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Humans; Multicenter Studies as Topic; Myeloid Differentiation Factor 88; Neoplasm Proteins; NF-kappa B; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Receptors, CXCR4; Recurrence; Salvage Therapy; Signal Transduction; Treatment Outcome; Waldenstrom Macroglobulinemia	2020
How to Sequence Therapies in Waldenström Macroglobulinemia. Current treatment options in oncology, 2021, 08-23, Volume: 22, Issue:10 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Humans; Mutation; Myeloid Differentiation Factor 88; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Waldenstrom Macroglobulinemia	2021
[Therapy of Waldenström´s macroglobulinaemia in the year 2014]. Vnitrni lekarstvi, 2014, Volume: 60, Issue:2 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Immunologic Factors; Immunosuppressive Agents; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Rituximab; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia	2014
Current and future therapeutic approach for Waldenström's macroglobulinemia. Immunotherapy, 2014, Volume: 6, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Disease Progression; Everolimus; Forecasting; Guillain-Barre Syndrome; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Immunotherapy; Incidence; Lenalidomide; Myelin-Associated Glycoprotein; Protein Kinase Inhibitors; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Thalidomide; Transplantation, Autologous; Treatment Outcome; Waldenstrom Macroglobulinemia; Watchful Waiting	2014
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood, 2014, Aug-28, Volume: 124, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia	2014
Biology, prognosis, and therapy of Waldenström Macroglobulinemia. Cancer treatment and research, 2015, Volume: 165 Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Everolimus; Humans; Piperidines; Prognosis; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy; Sirolimus; Stem Cell Transplantation; Waldenstrom Macroglobulinemia	2015
Waldenstrom macroglobulinemia: prognosis and management. Blood cancer journal, 2015, Mar-27, Volume: 5 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunoglobulin M; Lenalidomide; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia	2015
Treatment of plasma cell dyscrasias with lenalidomide. Leukemia, 2008, Volume: 22, Issue:7 Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Pyrazines; Renal Insufficiency; Thalidomide; Thromboembolism; Waldenstrom Macroglobulinemia	2008
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-01, Volume: 27, Issue:1 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous; Transplantation, Homologous; Waldenstrom Macroglobulinemia	2009
Bortezomib and Waldenstrom's macroglobulinemia. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:5 Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Pyrazines; Waldenstrom Macroglobulinemia	2009
Bortezomib in relapsed or refractory Waldenström's macroglobulinemia. Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Pyrazines; Waldenstrom Macroglobulinemia	2009
Role of proteasome inhibition in Waldenström's macroglobulinemia. Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:1 Topics: Boronic Acids; Bortezomib; Humans; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Waldenstrom Macroglobulinemia	2009
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leukemia & lymphoma, 2009, Volume: 50, Issue:5 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Waldenstrom Macroglobulinemia	2009
Bortezomib as a treatment option in patients with Waldenström macroglobulinemia. Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2 Topics: Alkylating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; B-Lymphocytes; Boronic Acids; Bortezomib; Humans; Nucleosides; Pyrazines; Recurrence; Rituximab; Signal Transduction; Waldenstrom Macroglobulinemia	2010
[Malignant lymphoma: individualized treatment according to biological and clinical risk factors]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:14 Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Ki-1 Antigen; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Precision Medicine; Prognosis; Pyrazines; Risk Factors; Rituximab; Survival Rate; Waldenstrom Macroglobulinemia	2011
Anti-angiogenic therapies in the treatment of Waldenstrom's Macroglobulinemia. Current cancer drug targets, 2011, Volume: 11, Issue:9 Topics: Angiogenesis Inhibitors; Bone Marrow; Boronic Acids; Bortezomib; Endothelial Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Panobinostat; Protease Inhibitors; Proteasome Inhibitors; Protein Kinase C; Pyrazines; TOR Serine-Threonine Kinases; Tumor Microenvironment; Waldenstrom Macroglobulinemia	2011
Waldenström macroglobulinemia: my way. Leukemia & lymphoma, 2013, Volume: 54, Issue:3 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Pyrazines; Rituximab; Survival Analysis; Thalidomide; Waldenstrom Macroglobulinemia	2013
Novel biologically based therapies for Waldenstrom's macroglobulinemia. Seminars in oncology, 2003, Volume: 30, Issue:2 Topics: Adjuvants, Immunologic; Anti-Bacterial Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Enzyme Inhibitors; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Protease Inhibitors; Pyrazines; Thalidomide; Thiazoles; Waldenstrom Macroglobulinemia	2003
Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert review of anticancer therapy, 2006, Volume: 6, Issue:7 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma; Pyrazines; Waldenstrom Macroglobulinemia	2006

Trials

11 trial(s) available for pyrazines and Waldenstrom Macroglobulinemia

Article	Year
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. The Lancet. Haematology, 2020, Volume: 7, Issue:2 Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Neoplasm Proteins; Neutropenia; Pain; Protein Kinase Inhibitors; Pyrazines; Quality of Life; Recurrence; Respiratory Tract Infections; Salvage Therapy; Treatment Outcome; Waldenstrom Macroglobulinemia	2020
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. British journal of haematology, 2019, Volume: 184, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Indazoles; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Proteins; Pyrazines; Syk Kinase; Waldenstrom Macroglobulinemia	2019
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood, 2013, Nov-07, Volume: 122, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Immunoglobulin M; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia	2013
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Viscosity; Bone Marrow Neoplasms; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematocrit; Herpes Zoster; Humans; Immunoglobulin M; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Count; Pyrazines; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia	2009
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Mar-10, Volume: 28, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunoglobulin M; Male; Middle Aged; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Rituximab; Survival Analysis; Waldenstrom Macroglobulinemia	2010
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. American journal of hematology, 2010, Volume: 85, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Pyrazines; Rituximab; Time Factors; Waldenstrom Macroglobulinemia	2010
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. British journal of haematology, 2010, Volume: 151, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia	2010
The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-01, Volume: 17, Issue:9 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Immunoglobulin Light Chains; Male; Pyrazines; Rituximab; Treatment Outcome; Waldenstrom Macroglobulinemia	2011
The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. American journal of hematology, 2011, Volume: 86, Issue:7 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Pyrazines; Radiography; Radiopharmaceuticals; Rituximab; Waldenstrom Macroglobulinemia	2011
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Apr-20, Volume: 25, Issue:12 Topics: Aged; Aged, 80 and over; Ambulatory Care; Boronic Acids; Bortezomib; Canada; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Probability; Protease Inhibitors; Pyrazines; Risk Assessment; Salvage Therapy; Severity of Illness Index; Survival Rate; Treatment Outcome; Waldenstrom Macroglobulinemia	2007
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jun-01, Volume: 13, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Humans; Immunoglobulin M; Male; Middle Aged; Pyrazines; Recurrence; Time Factors; Treatment Outcome; Waldenstrom Macroglobulinemia	2007

Other Studies

21 other study(ies) available for pyrazines and Waldenstrom Macroglobulinemia

Article	Year
Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up. Journal of clinical and experimental hematopathology : JCEH, 2013, Volume: 53, Issue:1 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunohistochemistry; Multiple Myeloma; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia	2013
Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Melphalan; Middle Aged; Multimodal Imaging; Osteolysis; Positron-Emission Tomography; Pyrazines; Recurrence; Remission Induction; Rituximab; Tomography, X-Ray Computed; Waldenstrom Macroglobulinemia; Zoledronic Acid	2013
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia. British journal of haematology, 2014, Volume: 164, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gossypol; Humans; Lenalidomide; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia	2014
Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia. BMJ case reports, 2014, Mar-26, Volume: 2014 Topics: Age Factors; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Fasciitis, Necrotizing; Fatal Outcome; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia	2014
Persistent dizziness. Journal of the American Geriatrics Society, 2015, Volume: 63, Issue:1 Topics: Aged; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Dizziness; Drug Therapy, Combination; Female; Humans; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia	2015
Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. American journal of hematology, 2015, Volume: 90, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Pyrazines; Retrospective Studies; Waldenstrom Macroglobulinemia	2015
How I treat Waldenström macroglobulinemia. Blood, 2015, Aug-06, Volume: 126, Issue:6 Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia	2015
microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood, 2009, Apr-30, Volume: 113, Issue:18 Topics: Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Case-Control Studies; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Lymphocytes; Male; Mice; MicroRNAs; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasms, Experimental; NF-kappa B; Oligonucleotide Array Sequence Analysis; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins c-akt; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Rituximab; RNA, Messenger; Signal Transduction; Waldenstrom Macroglobulinemia	2009
[Waldenström's macroglobulinemia]. La Revue de medecine interne, 2010, Volume: 31, Issue:5 Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Diagnosis, Differential; Humans; Male; Nucleosides; Phosphorylcholine; Prognosis; Protease Inhibitors; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia	2010
Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-01, Volume: 17, Issue:7 Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Caspases; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Chemokine CXCL12; Chymotrypsin; Coculture Techniques; DNA Fragmentation; Drug Synergism; Enzyme Activation; Female; Humans; JNK Mitogen-Activated Protein Kinases; Lymphoma; Mice; Mice, SCID; Oligopeptides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteasome Inhibitors; Pyrazines; Serine Proteinase Inhibitors; Unfolded Protein Response; Waldenstrom Macroglobulinemia	2011
Cutaneous macroglobulinosis treated with bortezomib and rituximab. European journal of haematology, 2011, Volume: 87, Issue:1 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Humans; Immunoglobulin M; Male; Pyrazines; Recurrence; Rituximab; Skin Diseases; Waldenstrom Macroglobulinemia	2011
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia. Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Male; Polymerase Chain Reaction; Pyrazines; Waldenstrom Macroglobulinemia	2011
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells. Leukemia & lymphoma, 2011, Volume: 52, Issue:9 Topics: Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; p38 Mitogen-Activated Protein Kinases; Pyrazines; Stress, Physiological; Vorinostat; Waldenstrom Macroglobulinemia	2011
Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Dec-15, Volume: 18, Issue:24 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Bone Marrow; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cell Survival; Clinical Trials, Phase II as Topic; Drug Synergism; Everolimus; Humans; Mechanistic Target of Rapamycin Complex 1; MicroRNAs; Multiprotein Complexes; Pyrazines; Rituximab; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Cells, Cultured; Tumor Microenvironment; Waldenstrom Macroglobulinemia	2012
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia. Clinical lymphoma, myeloma & leukemia, 2012, Volume: 12, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Disease Progression; Disease-Free Survival; Genetic Predisposition to Disease; Humans; Middle Aged; Pyrazines; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia	2012
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. British journal of haematology, 2013, Volume: 160, Issue:2 Topics: Antibodies, Monoclonal; Antimetabolites; Bone Marrow Examination; Boronic Acids; Bortezomib; Densitometry; Disease Progression; Disease-Free Survival; Forecasting; Hematopoiesis; Humans; Immunoglobulin Light Chains; Immunoglobulin M; Immunosuppressive Agents; Neoplasm, Residual; Nephelometry and Turbidimetry; Positron-Emission Tomography; Pyrazines; Remission Induction; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Waldenstrom Macroglobulinemia	2013
Waldenström's macroglobulinemia and bortezomib. Haematologica, 2005, Volume: 90, Issue:12 Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Diseases; Humans; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Waldenstrom Macroglobulinemia	2005
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib. Haematologica, 2005, Volume: 90, Issue:12 Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Waldenstrom Macroglobulinemia	2005
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood, 2008, May-01, Volume: 111, Issue:9 Topics: Boronic Acids; Bortezomib; Cell Adhesion; Cell Death; Cell Movement; Cells, Cultured; Drug Delivery Systems; Drug Synergism; Humans; Lactones; Proteasome Inhibitors; Pyrazines; Pyrroles; Waldenstrom Macroglobulinemia	2008
Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood, 2008, May-15, Volume: 111, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; NF-kappa B; Phosphorylcholine; Pyrazines; Signal Transduction; Waldenstrom Macroglobulinemia	2008
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-15, Volume: 14, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Drug Evaluation, Preclinical; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukocytes; Oligonucleotide Array Sequence Analysis; Pyrazines; Resveratrol; Signal Transduction; Stilbenes; TCF Transcription Factors; Vidarabine; Waldenstrom Macroglobulinemia	2008